Anti-IL-13 Antibody (Cendakimab)
Catalog No.
F1270
Anti-IL-13 Antibody (Cendakimab)
Featured Products
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized recombinant monoclonal antibody against IL-13. Cendakimab has high affinity and potency for human wild-type and variant IL-13 and blocks the binding of IL-13 to IL-13Rα1 and IL-13Rα2 with IC50 of 352 pM and 631 pM, respectively, as determined by ELISA. Cendakimab recognizes wild-type human IL-13 and the common polymorphic variant R110Q with binding potencies of 52 pM and 50 pM, respectively. Cendakimab has the potential to be used in IL-13-related allergic/inflammatory diseases such as asthma and eosinophilic esophagitis.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
2151032-62-9
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
ABT-308, 13C5.5, RPC4046
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P35225
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
IL-13
Please avoid freeze-thaw cycles.